Activation of virus replication after vaccination of HIV-1-infected individuals
- PMID: 7500017
- PMCID: PMC2192265
- DOI: 10.1084/jem.182.6.1727
Activation of virus replication after vaccination of HIV-1-infected individuals
Abstract
Little is known about the factors that govern the level of HIV-1 replication in infected individuals. Recent studies (using potent antiviral drugs) of the kinetics of HIV-1 replication in vivo have demonstrated that steady-state levels of viremia are sustained by continuous rounds of de novo infection and the associated rapid turnover of CD4+ T lymphocytes. However, no information is available concerning the biologic variables that determine the size of the pool of T cells that are susceptible to virus infection or the amount of virus produced from infected cells. Furthermore, it is not known whether all CD4+ T lymphocytes are equally susceptible to HIV-1 infection at a given time or whether the infection is focused on cells of a particular state of activation or antigenic specificity. Although HIV-1 replication in culture is known to be greatly facilitated by T cell activation, the ability of specific antigenic stimulation to augment HIV-1 replication in vivo has not been studied. We sought to determine whether vaccination of HIV-1-infected adults leads to activation of virus replication and the targeting of vaccine antigen-responsive T cells for virus infection and destruction. Should T cell activation resulting from exposure to environmental antigens prove to be an important determinant of the steady-state levels of HIV-1 replication in vivo and lead to the preferential loss of specific populations of CD4+ T lymphocytes, it would have significant implications for our understanding of and therapeutic strategies for HIV-1 disease. To begin to address these issues, HIV-1-infected individuals and uninfected controls were studied by measurement of immune responses to influenza antigens and quantitation of virion-associated plasma HIV-1 RNA levels at baseline and at intervals after immunization with the trivalent influenza vaccine. Influenza vaccination resulted in readily demonstrable but transient increases in plasma HIV-1 RNA levels, indicative of activation of viral replication, in HIV-1-infected individuals with preserved ability to immunologically respond to vaccine antigens. Activation of HIV-1 replication by vaccination was more often seen and of greater magnitude in individuals who displayed a T cell proliferative response to vaccine antigens at baseline and in those who mounted a significant serologic response after vaccination. The fold increase in viremia, as well as the rates of increase of HIV-1 in plasma after vaccination and rates of viral decline after peak viremia, were higher in individuals with higher CD4+ T cell counts.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
T cell activation and human immunodeficiency virus replication after influenza immunization of infected children.Pediatr Infect Dis J. 1996 Mar;15(3):197-203. doi: 10.1097/00006454-199603000-00004. Pediatr Infect Dis J. 1996. PMID: 8852906
-
Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals.Hum Vaccin Immunother. 2015;11(9):2253-65. doi: 10.1080/21645515.2015.1051275. Epub 2015 Jun 19. Hum Vaccin Immunother. 2015. PMID: 26091502 Free PMC article.
-
Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients.AIDS. 1997 Jul;11(8):1013-21. doi: 10.1097/00002030-199708000-00010. AIDS. 1997. PMID: 9223736 Clinical Trial.
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
-
Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts.J Clin Virol. 2003 Apr;26(3):307-15. doi: 10.1016/s1386-6532(02)00047-1. J Clin Virol. 2003. PMID: 12637080 Review.
Cited by
-
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.Clin Infect Dis. 2013 Sep;57(5):735-44. doi: 10.1093/cid/cit319. Epub 2013 May 10. Clin Infect Dis. 2013. PMID: 23667266 Free PMC article. Clinical Trial.
-
Antigenic stimulation specifically reactivates the replication of archived simian immunodeficiency virus genomes in chronically infected macaques.J Virol. 2005 Sep;79(17):11231-8. doi: 10.1128/JVI.79.17.11231-11238.2005. J Virol. 2005. PMID: 16103175 Free PMC article.
-
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults.Clin Vaccine Immunol. 2008 Feb;15(2):253-9. doi: 10.1128/CVI.00316-07. Epub 2007 Nov 14. Clin Vaccine Immunol. 2008. PMID: 18003811 Free PMC article. Clinical Trial.
-
Transcriptional and Immunologic Correlates of Response to Pandemic Influenza Vaccine in Aviremic, HIV-Infected Children.Front Immunol. 2021 Mar 25;12:639358. doi: 10.3389/fimmu.2021.639358. eCollection 2021. Front Immunol. 2021. PMID: 33868267 Free PMC article.
-
Variable effect of co-infection on the HIV infectivity: within-host dynamics and epidemiological significance.Theor Biol Med Model. 2012 Mar 19;9:9. doi: 10.1186/1742-4682-9-9. Theor Biol Med Model. 2012. PMID: 22429506 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials